Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen: clinical trials recruiting now

Fewer than 3 recruiting trials found.

Phase breakdown

Conditions being studied

Recruiting trials involving Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen

• Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)
  NCT07190443 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study
  NCT07581834 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 2 locations

Common questions

How many recruiting trials involve Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen?

2 recruiting trials across 10 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.